- |||||||||| RA101295 / UCB
Journal: Simultaneous C5 and CD14 inhibition limits inflammation and organ dysfunction in pig polytrauma. (Pubmed Central) - Sep 14, 2022
The therapy group received intravenously C5 inhibitor (RA101295) and anti-CD14 antibody (rMil2) 30 min post-trauma...In kidney and liver, the C5b-9 deposition was similarly detected mainly the untreated as compared to the treated animals. Combined C5 and CD14 inhibition limited the inflammatory response, the organ damage, and reduced the catecholamine requirements after experimental polytrauma and might be a promising therapeutic approach.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Journal: Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. (Pubmed Central) - Feb 17, 2022
We show that whereas complement factor 5 (C5) cleavage inhibitor eculizumab blocks all neutrophil anti-microbial functions, newer compounds like the C5 cleavage inhibitor RA101295 and C5a receptor antagonist avacopan inhibit chemotaxis and swarming while preserving neutrophil phagocytosis. These results highlight the utility of microfluidic neutrophil assays in evaluating potential complement-targeting therapeutics.
|
